Sirtuin family: A link to metabolic signaling and senescence

Current Medicinal Chemistry

Volumn 17, Issue 26, 2010, Pages 2921-2932

  Kyrylenko, S ^a,b,c   Baniahmad, A ^b,c  

^a MASARYK UNIVERSITY   (Czech Republic)

^b JENA UNIVERSITY HOSPITAL   (Germany)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Cellular senescence; Histone deacetylase; Lifespan; Metabolism; Nad; Oaadpr; P53; Resveratrol

Indexed keywords

ADENOSINE DIPHOSPHATE RIBOSE ACETATE; NICOTINAMIDE ADENINE DINUCLEOTIDE; RESVERATROL; SIRTUIN;

ARTICLE; CELL CYCLE; CELL METABOLISM; CELL SURVIVAL; DRUG MECHANISM; HOMEOSTASIS; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SENESCENCE;

AGING; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; NAD; SIGNAL TRANSDUCTION; SIRTUINS; STILBENES;

EID: 77955608578     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710792065009     Document Type: Article

References (125)

1. Brachmann, C.B.; Sherman, J.M.; Devine, S.E.; Cameron, E.E.; Pillus, L.; Boeke, J.D. The SIR2 gene family, conserved from bacteria to humans, functions in silencing, cell cycle progression, and chromosome stability. Genes Dev., 1995, 9, 2888-2902.
2. Braunstein, M.; Rose, A.B.; Holmes, S.G.; Allis, C.D.; Broach, J.R. Transcriptional silencing in yeast is associated with reduced nu-cleosome acetylation. Genes Dev., 1993, 7, 592-604.
3. Gottlieb, S.; Esposito, R.E. A new role for a yeast transcriptional silencer gene, SIR2, in regulation of recombination in ribosomal DNA. Cell, 1989, 56, 771-776.
4. Frye, R.A. Characterization of five human cDNAs with homology to the yeast SIR2 gene: Sir2-like proteins (sirtuins) metabolize NAD and may have protein ADP-ribosyltransferase activity. Bio-chem. Biophys. Res. Commun., 1999, 260, 273-279.
5. Frye, R.A. Phylogenetic classification of prokaryotic and eukary-otic Sir2-like proteins. Biochem. Biophys. Res. Commun., 2000, 273, 793-798.
6. Oberdoerffer, P.; Michan, S.; McVay, M.; Mostoslavsky, R.; Vann, J.; Park, S.K.; Hartlerode, A.; Stegmuller, J.; Hafner, A.; Loerch, P.; Wright, S.M.; Mills, K.D.; Bonni, A.; Yankner, B.A.; Scully, R.; Prolla, T.A.; Alt, F.W.; Sinclair, D.A. SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging. Cell, 2008, 135, 907-918.
7. Lin, S.J.; Guarente, L. Nicotinamide adenine dinucleotide, a metabolic regulator of transcription, longevity and disease. Curr. Opin. Cell Biol., 2003, 15, 241-246.
8. McCay, C.M. Is longevity compatible with optimum growth? Science, 1933, 77, 410-411.
9. McCay, C.M. Effect of Restricted Feeding Upon Aging and Chronic Diseases in Rats and Dogs. Am. J. Public Health Nations Health, 1947, 37, 521-528.
10. Asher, G.; Gatfield, D.; Stratmann, M.; Reinke, H.; Dibner, C.; Kreppel, F.; Mostoslavsky, R.; Alt, F.W.; Schibler, U. SIRT1 regulates circadian clock gene expression through PER2 deacetylation. Cell, 2008, 134, 317-328.
11. Kaeberlein, M.; McVey, M.; Guarente, L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev., 1999, 13, 2570-2580.
12. Lin, S.J.; Defossez, P.A.; Guarente, L. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomy-ces cerevisiae. Science, 2000, 289, 2126-2128.
13. Tissenbaum, H.A.; Guarente, L. Increased dosage of a sir-2 gene extends lifespan in Caenorhabditis elegans. Nature, 2001, 410, 227-230.
14. Rogina, B.; Helfand, S.L. Sir2 mediates longevity in the fly through a pathway related to calorie restriction. Proc. Natl. Acad. Sci. U.S.A., 2004, 101, 15998-16003.
15. Brooks, C.L.; Gu, W. How does SIRT1 affect metabolism, senescence and cancer? Nat. Rev. Cancer, 2009, 9, 123-128.
16. Goligorsky, M.S.; Chen, J.; Patschan, S. Stress-induced premature senescence of endothelial cells: a perilous state between recovery and point of no return. Curr. Opin. Hematol., 2009, 16, 215-219.
17. Mantel, C.; Broxmeyer, H.E. Sirtuin 1, stem cells, aging, and stem cell aging. Curr. Opin. Hematol., 2008, 15, 326-331.
18. Altucci, L.; Minucci, S. Epigenetic therapies in haematological malignancies: searching for true targets. Eur. J. Cancer, 2009, 45, 1137-1145.
19. Altucci, L.; Stunnenberg, H.G. Time for epigenetics. Int. J. Bio-chem. Cell Biol., 2009, 41, 2-3.
20. Tanny, J.C.; Dowd, G.J.; Huang, J.; Hilz, H.; Moazed, D. An enzymatic activity in the yeast Sir2 protein that is essential for gene silencing. Cell, 1999, 99, 735-745.
21. Landry, J.; Slama, J.T.; Sternglanz, R. Role of NAD(+) in the deacetylase activity of the SIR2-like proteins. Biochem. Biophys. Res. Commun., 2000, 278, 685-690.
22. Landry, J.; Sutton, A.; Tafrov, S.T.; Heller, R.C.; Stebbins, J.; Pillus, L.; Sternglanz, R. The silencing protein SIR2 and its ho-mologs are NAD-dependent protein deacetylases. Proc. Natl. Acad. Sci. U.S.A., 2000, 97, 5807-5811.
23. Imai, S.; Armstrong, C.M.; Kaeberlein, M.; Guarente, L. Transcrip-tional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature, 2000, 403, 795-800.
24. Schmidt, M.T.; Smith, B.C.; Jackson, M.D.; Denu, J.M. Coenzyme specificity of Sir2 protein deacetylases: implications for physiological regulation. J. Biol. Chem., 2004, 279, 40122-40129.
25. Sauve, A.A.; Celic, I.; Avalos, J.; Deng, H.; Boeke, J.D.; Schramm, V.L. Chemistry of gene silencing: the mechanism of NAD+-dependent deacetylation reactions. Biochemistry, 2001, 40, 15456-15463.
26. Sauve, A.A.; Schramm, V.L. SIR2: the biochemical mechanism of NAD(+)-dependent protein deacetylation and ADP-ribosyl enzyme intermediates. Curr. Med. Chem., 2004, 11, 807-826.
27. Hawse, W.F.; Hoff, K.G.; Fatkins, D.G.; Daines, A.; Zubkova, O.V.; Schramm, V.L.; Zheng, W.; Wolberger, C. Structural insights into intermediate steps in the Sir2 deacetylation reaction. Structure, 2008, 16, 1368-1377.
28. Sauve, A.A. Sirtuin chemical mechanisms. Biochim. Biophys. Acta, 2010, Epub Feb 2, DOI 016/j.bbapap.2010.01.021.
29. Hoff, K.G.; Wolberger, C. Getting a grip on O-acetyl-ADP-ribose. Nat. Struct. Mol. Biol., 2005, 12, 560-561.
30. Haigis, M.C.; Guarente, L.P. Mammalian sirtuins--emerging roles in physiology, aging, and calorie restriction. Genes Dev., 2006, 20, 2913-2921.
31. Guarente, L. Sir2 links chromatin silencing, metabolism, and aging. Genes Dev., 2000, 14, 1021-1026.
32. Belenky, P.; Racette, F.G.; Bogan, K.L.; McClure, J.M.; Smith, J.S.; Brenner, C. Nicotinamide riboside promotes Sir2 silencing and extends lifespan via Nrk and Urh1/Pnp1/Meu1 pathways to NAD+. Cell, 2007, 129, 473-484.
33. Yang, H.; Yang, T.; Baur, J.A.; Perez, E.; Matsui, T.; Carmona, J.J.; Lamming, D.W.; Souza-Pinto, N.C.; Bohr, V.A.; Rosenzweig, A.; de Cabo, R.; Sauve, A.A.; Sinclair, D.A. Nutrient-sensitive mi-tochondrial NAD+ levels dictate cell survival. Cell, 2007, 130, 1095-1107.
34. Tanner, K.G.; Landry, J.; Sternglanz, R.; Denu, J.M. Silent information regulator 2 family of NAD- dependent histone/protein deacetylases generates a unique product, 1-O-acetyl-ADP-ribose. Proc. Natl. Acad. Sci. U.S.A., 2000, 97, 14178-14182.
35. Tanny, J.C.; Moazed, D. Coupling of histone deacetylation to NAD breakdown by the yeast silencing protein Sir2: Evidence for acetyl transfer from substrate to an NAD breakdown product. Proc. Natl. Acad. Sci. U.S.A., 2001, 98, 415-420.
36. Vaquero, A.; Scher, M.; Lee, D.; Erdjument-Bromage, H.; Tempst, P.; Reinberg, D. Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin. Mol. Cell, 2004, 16, 93-105.
37. Jackson, M.D.; Denu, J.M. Structural identification of 2'- and 3'-O-acetyl-ADP-ribose as novel metabolites derived from the Sir2 family of beta -NAD+-dependent histone/protein deacetylases. J. Biol. Chem., 2002, 277, 18535-18544.
38. Borra, M.T.; O'Neill, F.J.; Jackson, M.D.; Marshall, B.; Verdin, E.; Foltz, K.R.; Denu, J.M. Conserved enzymatic production and biological effect of O-acetyl-ADP-ribose by silent information regulator 2-like NAD+-dependent deacetylases. J. Biol. Chem., 2002, 277, 12632-12641.
39. Grubisha, O.; Rafty, L.A.; Takanishi, C.L.; Xu, X.; Tong, L.; Per-raud, A.L.; Scharenberg, A.M.; Denu, J.M. Metabolite of SIR2 reaction modulates TRPM2 ion channel. J. Biol. Chem., 2006, 281, 14057-14065.
40. Rafty, L.A.; Schmidt, M.T.; Perraud, A.L.; Scharenberg, A.M.; Denu, J.M. Analysis of O-acetyl-ADP-ribose as a target for Nudix ADP-ribose hydrolases. J. Biol. Chem., 2002, 277, 47114-47122.
41. Tong, L.; Lee, S.; Denu, J.M. Hydrolase regulates NAD+ metabolites and modulates cellular redox. J. Biol. Chem., 2009, 284, 11256-11266.
42. Starai, V.J.; Takahashi, H.; Boeke, J.D.; Escalante-Semerena, J.C. A link between transcription and intermediary metabolism: a role for Sir2 in the control of acetyl-coenzyme A synthetase. Curr. Opin. Microbiol., 2004, 7, 115-119.
43. Ono, T.; Kasamatsu, A.; Oka, S.; Moss, J. The 39-kDa poly(ADP-ribose) glycohydrolase ARH3 hydrolyzes O-acetyl-ADP-ribose, a product of the Sir2 family of acetyl-histone deacetylases. Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 16687-16691.
44. Liou, G.G.; Tanny, J.C.; Kruger, R.G.; Walz, T.; Moazed, D. Assembly of the SIR complex and its regulation by O-acetyl-ADP-ribose, a product of NAD-dependent histone deacetylation. Cell, 2005, 121, 515-527.
45. Kustatscher, G.; Hothorn, M.; Pugieux, C.; Scheffzek, K.; Ladurner, A.G. Splicing regulates NAD metabolite binding to histone macroH2A. Nat. Struct. Mol. Biol., 2005, 12, 624-625.
46. Chou, C.C.; Li, Y.C.; Gartenberg, M.R. Bypassing Sir2 and O-acetyl-ADP-ribose in transcriptional silencing. Mol. Cell, 2008, 31, 650-659.
47. Ehrentraut, S.; Weber, J.M.; Dybowski, J.N.; Hoffmann, D.; Ehr-enhofer-Murray, A.E. Rpd3-dependent boundary formation at te-lomeres by removal of Sir2 substrate. Proc. Natl. Acad. Sci. U.S.A., 2010, 107, 5522-5527.
48. Lee, S.; Tong, L.; Denu, J.M. Quantification of endogenous sirtuin metabolite O-acetyl-ADP-ribose. Anal. Biochem., 2008, 383, 174-179.
49. Dzeja, P. P.; Terzic, A. Mitochondria-Nucleus Energetic Communication: Role for Phosphotransfer Networks in Processing Cellular Information. In Handbook of Neurochemistry and Molecular Neu-robiology; Lajtha, A., Ed.; Springer US: 2007; pp. 641-666.
50. Schulz, T.J.; Zarse, K.; Voigt, A.; Urban, N.; Birringer, M.; Ristow, M. Glucose restriction extends Caenorhabditis elegans life span by inducing mitochondrial respiration and increasing oxidative stress. Cell Metab., 2007, 6, 280-293.
51. Min, J.; Landry, J.; Sternglanz, R.; Xu, R.M. Crystal structure of a SIR2 homolog-NAD complex. Cell, 2001, 105, 269-279.
52. Belenky, P.; Bogan, K.L.; Brenner, C. NAD+ metabolism in health and disease. Trends Biochem. Sci., 2007, 32, 12-19.
53. Baur, J.A.; Sinclair, D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug Discov., 2006, 5, 493-506.
54. Brisdelli, F.; D'Andrea, G.; Bozzi, A. Resveratrol: a natural poly-phenol with multiple chemopreventive properties. Curr. Drug Metab., 2009, 10, 530-546.
55. Sadruddin, S.; Arora, R. Resveratrol: biologic and therapeutic implications. J. Cardiometab. Syndr., 2009, 4, 102-106.
56. Kaeberlein, M.; McDonagh, T.; Heltweg, B.; Hixon, J.; Westman, E A.; Caldwell, S.D.; Napper, A.; Curtis, R.; DiStefano, P.S.; Fields, S.; Bedalov, A.; Kennedy, B.K. Substrate-specific activation of sirtuins by resveratrol. J. Biol. Chem., 2005, 280, 17038-17045.
57. Borra, M.T.; Smith, B.C.; Denu, J.M. Mechanism of human SIRT1 activation by resveratrol. J. Biol. Chem., 2005, 280, 17187-17195.
58. Alvira, D.; Yeste-Velasco, M.; Folch, J.; Verdaguer, E.; Canudas, A.M.; Pallas, M.; Camins, A. Comparative analysis of the effects of resveratrol in two apoptotic models: inhibition of complex I and potassium deprivation in cerebellar neurons. Neuroscience, 2007, 147, 746-756.
59. Stefani, M.; Markus, M.A.; Lin, R.C.; Pinese, M.; Dawes, I.W.; Morris, B.J. The effect of resveratrol on a cell model of human aging. Ann. N. Y. Acad. Sci., 2007, 1114, 407-418.
60. Frojdo, S.; Cozzone, D.; Vidal, H.; Pirola, L. Resveratrol is a class IA phosphoinositide 3-kinase inhibitor. Biochem. J., 2007, 406, 511-518.
61. Buryanovskyy, L.; Fu, Y.; Boyd, M.; Ma, Y.; Hsieh, T.C.; Wu, J.M.; Zhang, Z. Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry, 2004, 43, 11417-11426.
62. Beher, D.; Wu, J.; Cumine, S.; Kim, K.W.; Lu, S.C.; Atangan, L.; Wang, M. Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem. Biol. Drug Des., 2009, 74, 619-624.
63. Pacholec, M.; Chrunyk, B.A.; Cunningham, D.; Flynn, D.; Griffith, D.A.; Griffor, M.; Loulakis, P.; Pabst, B.; Qiu, X.; Stockman, B.; Thanabal, V.; Varghese, A.; Ward, J.; Withka, J.; Ahn, K. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J. Biol. Chem., 2010, 285, 8340-8351
64. Tang, B.L. Resveratrol is neuroprotective because it is not a direct activator of Sirt1-A hypothesis. Brain Res. Bull., 2010, 81, 359-361.
65. Westphal, C.H.; Dipp, M.A.; Guarente, L. A therapeutic role for sirtuins in diseases of aging? Trends Biochem. Sci., 2007, 32, 555-560.
66. Sauve, A.A.; Moir, R.D.; Schramm, V.L.; Willis, I.M. Chemical activation of Sir2-dependent silencing by relief of nicotinamide inhibition. Mol. Cell, 2005, 17, 595-601.
67. Sauve, A.A.; Schramm, V.L. Sir2 regulation by nicotinamide results from switching between base exchange and deacetylation chemistry. Biochemistry, 2003, 42, 9249-9256.
68. Mai, A.; Valente, S.; Meade, S.; Carafa, V.; Tardugno, M.; Nebbioso, A.; Galmozzi, A.; Mitro, N.; De Fabiani, E.; Altucci, L.; Ka-zantsev, A. Study of 1,4-dihydropyridine structural scaffold: discovery of novel sirtuin activators and inhibitors. J. Med. Chem., 2009, 52, 5496-5504.
69. Sauve, A.A. Pharmaceutical strategies for activating sirtuins. Curr. Pharm. Des., 2009, 15, 45-56.
70. Alexeyev, M.F. Is there more to aging than mitochondrial DNA and reactive oxygen species? FEBS J., 2009, 276, 5768-5787.
71. Colman, R.J.; Anderson, R.M.; Johnson, S.C.; Kastman, E.K.; Kosmatka, K.J.; Beasley, T.M.; Allison, D.B.; Cruzen, C.; Simmons, H.A.; Kemnitz, J.W.; Weindruch, R. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science, 2009, 325, 201-204.
72. Masoro, E.J. Caloric restriction and aging: an update. Exp. Gerontol., 2000, 35, 299-305.
73. Mair, W.; Dillin, A. Aging and survival: the genetics of life span extension by dietary restriction. Annu. Rev. Biochem., 2008, 77, 727-754.
74. Toussaint, O.; Dumont, P.; Dierick, J.F.; Pascal, T.; Frippiat, C.; Chainiaux, F.; Sluse, F.; Eliaers, F.; Remacle, J. Stress-induced premature senescence. Essence of life, evolution, stress, and aging. Ann. N. Y. Acad. Sci., 2000, 908, 85-98.
75. Dimri, G.P.; Lee, X.; Basile, G.; Acosta, M.; Scott, G.; Roskelley, C.; Medrano, E.E.; Linskens, M.; Rubelj, I.; Pereira-Smith, O. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. U.S.A., 1995, 92, 9363-9367.
76. Narita, M.; Nunez, S.; Heard, E.; Narita, M.; Lin, A.W.; Hearn, S.A.; Spector, D.L.; Hannon, G.J.; Lowe, S.W. Rb-mediated het-erochromatin formation and silencing of E2F target genes during cellular senescence. Cell, 2003, 113, 703-716.
77. Sasaki, T.; Maier, B.; Bartke, A.; Scrable, H. Progressive loss of SIRT1 with cell cycle withdrawal. Aging Cell, 2006, 5, 413-422.
78. Maier, A.B.; Westendorp, R.G. Relation between replicative senescence of human fibroblasts and life history characteristics. Ageing Res. Rev., 2009, 8, 237-243.
79. Hwang, E.S.; Yoon, G.; Kang, H.T. A comparative analysis of the cell biology of senescence and aging. Cell Mol. Life Sci., 2009, 66, 2503-2524.
80. Ohtani, N.; Mann, D.J.; Hara, E. Cellular senescence: its role in tumor suppression and aging. Cancer Sci., 2009, 100, 792-797.
81. Finkel, T.; Deng, C.X.; Mostoslavsky, R. Recent progress in the biology and physiology of sirtuins. Nature, 2009, 460, 587-591.
82. Uhl, M.; Csernok, A.; Aydin, S.; Kreienberg, R.; Wiesmuller, L.; Gatz, S. A. Role of SIRT1 in homologous recombination. DNA Repair (Amst), 2010, 9, 383-389.
83. Furukawa, A.; Tada-Oikawa, S.; Kawanishi, S.; Oikawa, S. H2O2 accelerates cellular senescence by accumulation of acetylated p53 via decrease in the function of SIRT1 by NAD+ depletion. Cell Physiol. Biochem., 2007, 20, 45-54.
84. Mizutani, H.; Tada-Oikawa, S.; Hiraku, Y.; Oikawa, S.; Kojima, M.; Kawanishi, S. Mechanism of apoptosis induced by a new topoisomerase inhibitor through the generation of hydrogen peroxide. J. Biol. Chem., 2002, 277, 30684-30689.
85. Luo, J.; Nikolaev, A.Y.; Imai, S.; Chen, D.; Su, F.; Shiloh, A.; Guarente, L.; Gu, W. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell, 2001, 107, 137-148.
86. Chen, Q.M.; Liu, J.; Merrett, J.B. Apoptosis or senescence-like growth arrest: influence of cell-cycle position, p53, p21 and bax in 2932 Current Medicinal Chemistry, 2010 Vol. 17, No. 26 H2O2 response of normal human fibroblasts. Biochem. J., 2000, 347, 543-551.
87. Vaziri, H.; Dessain, S.K.; Ng Eaton, E.; Imai, S.I.; Frye, R.A.; Pandita, T.K.; Guarente, L.; Weinberg, R.A. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell, 2001, 107, 149-159.
88. Langley, E.; Pearson, M.; Faretta, M.; Bauer, U.M.; Frye, R.A.; Minucci, S.; Pelicci, P.G.; Kouzarides, T. Human SIR2 deacety-lates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J., 2002, 21, 2383-2396.
89. Ota, H.; Akishita, M.; Eto, M.; Iijima, K.; Kaneki, M.; Ouchi, Y. Sirt1 modulates premature senescence-like phenotype in human endothelial cells. J. Mol. Cell Cardiol., 2007, 43, 571-579.
90. Ota, H.; Tokunaga, E.; Chang, K.; Hikasa, M.; Iijima, K.; Eto, M.; Kozaki, K.; Akishita, M.; Ouchi, Y.; Kaneki, M. Sirt1 inhibitor, Sirtinol, induces senescence-like growth arrest with attenuated Ras-MAPK signaling in human cancer cells. Oncogene, 2006, 25, 176-185.
91. Wang, F.; Nguyen, M.; Qin, F.X.; Tong, Q. SIRT2 deacetylates F0X03a in response to oxidative stress and caloric restriction. Aging Cell, 2007, 6, 505-514.
92. McGlynn, L.M.; Stevenson, K.; Lamb, K.; Zino, S.; Brown, M.; Prina, A.; Kingsmore, D.; Shiels, P.G. Cellular senescence in pre-transplant renal biopsies predicts postoperative organ function. Aging Cell, 2009, 8, 45-51.
93. Salminen, A.; Suuronen, T.; Huuskonen, J.; Kaarniranta, K. NEM0 shuttle: a link between DNA damage and NF-kappaB activation in progeroid syndromes? Biochem. Biophys. Res. Commun., 2008, 367, 715-718.
94. Menghini, R.; Casagrande, V.; Cardellini, M.; Martelli, E.; Terri-noni, A.; Amati, F.; Vasa-Nicotera, M.; Ippoliti, A.; Novelli, G.; Melino, G.; Lauro, R.; Federici, M. MicroRNA 217 modulates en-dothelial cell senescence via silent information regulator 1. Circulation, 2009, 120, 1524-1532.
95. Ho, C.; van der Veer, E.; Akawi, O Pickering, J.G. SIRT1 markedly extends replicative lifespan if the NAD+ salvage pathway is enhanced. FEBS Lett., 2009, 583, 3081-3085.
96. Tajes, M.; Gutierrez-Cuesta, J.; Ortuno-Sahagun, D.; Camins, A.; Pallas, M. Anti-aging properties of melatonin in an in vitro murine senescence model: involvement of the sirtuin 1 pathway. J. Pineal Res., 2009, 47, 228-237.
97. Imai, S.; Kiess, W. Therapeutic potential of SIRT1 and NAMPT-mediated NAD biosynthesis in type 2 diabetes. Front. Biosci., 2009, 14, 2983-2995.
98. Kuki, S.; Imanishi, T.; Kobayashi, K.; Matsuo, Y.; Obana, M.; Akasaka, T. Hyperglycemia accelerated endothelial progenitor cell senescence via the activation of p38 mitogen-activated protein kinase. Circ. J., 2006, 70, 1076-1081.
99. Picard, F.; Kurtev, M.; Chung, N.; Topark-Ngarm, A.; Senawong, T.; Machado De Oliveira, R.; Leid, M.; McBurney, M. W.; Guar-ente, L. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature, 2004, 429, 771-776.
100. Voutsadakis, I.A. Peroxisome proliferator-activated receptor gamma (PPARgamma) and colorectal carcinogenesis. J. Cancer Res. Clin. Oncol., 2007, 133, 917-928.
101. Wong, S.; Weber, J.D. Deacetylation of the retinoblastoma tumour suppressor protein by SIRT1. Biochem. J., 2007, 407, 451-460.
102. Huang, J.; Gan, Q.; Han, L.; Li, J.; Zhang, H.; Sun, Y.; Zhang, Z.; Tong, T. SIRT1 overexpression antagonizes cellular senescence with activated ERK/S6k1 signaling in human diploid fibroblasts. PLoS ONE, 2008, 3, e1710.
103. Kim, E.J.; Kho, J.H.; Kang, M.R.; Um, S.J. Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity. Mol. Cell, 2007, 28, 277-290.
104. Anantharaman, V.; Aravind, L. Analysis of DBC1 and its ho-mologs suggests a potential mechanism for regulation of sirtuin domain deacetylases by NAD metabolites. Cell Cycle, 2008, 7, 1467-1472.
105. Zhao, W.; Kruse, J.P.; Tang, Y.; Jung, S.Y.; Qin, J.; Gu, W. Negative regulation of the deacetylase SIRT1 by DBC1. Nature, 2008, 451, 587-590.
106. Kim, J.E.; Chen, J.; Lou, Z. DBC1 is a negative regulator of SIRT1. Nature, 2008, 451, 583-586.
107. Kim, J.E.; Lou, Z.; Chen, J. Interactions between DBC1 and SIRT 1 are deregulated in breast cancer cells. Cell Cycle, 2009, 8, 3784-3785.
108. Leibiger, I.B.; Berggren, P.O. Sirt1: a metabolic master switch that modulates lifespan. Nat. Med., 2006, 12, 34-6; discussion 36.
109. Rodgers, J.T.; Lerin, C.; Haas, W.; Gygi, S.P.; Spiegelman, B.M.; Puigserver, P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature, 2005, 434, 113-118.
110. Fulco, M.; Sartorelli, V. Comparing and contrasting the roles of AMPK and SIRT1 in metabolic tissues. Cell Cycle, 2008, 7, 3669-3679.
111. Canto, C.; Auwerx, J. Glucose restriction: longevity SIRTainly, but without building muscle? Dev. Cell, 2008, 14, 642-644.
112. Kim, E.J.; Um, S.J. SIRT1: roles in aging and cancer. BMB Rep., 2008, 41, 751-756.
113. Canto, C.; Auwerx, J. Caloric restriction, SIRT1 and longevity. Trends Endocrinol. Metab., 2009, 20, 325-331.
114. Chua, K.F.; Mostoslavsky, R.; Lombard, D.B.; Pang, W.W.; Saito, S.; Franco, S.; Kaushal, D.; Cheng, H.L.; Fischer, M.R.; Stokes, N.; Murphy, M.M.; Appella, E.; Alt, F.W. Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress. Cell Metab., 2005, 2, 67-76.
115. Alcendor, R.R.; Gao, S.; Zhai, P.; Zablocki, D.; Holle, E.; Yu, X.; Tian, B.; Wagner, T.; Vatner, S.F.; Sadoshima, J. Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ. Res., 2007, 100, 1512-1521.
116. Stunkel, W.; Peh, B.K.; Tan, Y.C.; Nayagam, V.M.; Wang, X.; Salto-Tellez, M.; Ni, B.; Entzeroth, M.; Wood, J. Function of the SIRT1 protein deacetylase in cancer. Biotechnol. J., 2007, 2, 1360-1368.
117. Cheng, H.L.; Mostoslavsky, R.; Saito, S.; Manis, J.P.; Gu, Y.; Patel, P.; Bronson, R.; Appella, E.; Alt, F.W.; Chua, K.F. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc. Natl. Acad. Sci. U.S.A., 2003, 100, 10794-10799.
118. McBurney, M.W.; Yang, X.; Jardine, K.; Hixon, M.; Boekelheide, K.; Webb, J.R.; ansdorp, P.M.; Lemieux, M. The mammalian SIR2alpha protein has a role in embryogenesis and gametogenesis. Mol. Cell Biol., 2003, 23, 38-54.
119. Han, M.K.; Song, E.K.; Guo, Y.; Ou, X.; Mantel, C.; Broxmeyer, H.E. SIRT1 regulates apoptosis and Nanog expression in mouse embryonic stem cells by controlling p53 subcellular localization. Cell Stem Cell, 2008, 2, 241-251.
120. Michishita, E.; Park, J.Y.; Burneskis, J.M.; Barrett, J.C.; Horikawa, I. Evolutionarily conserved and nonconserved cellular localizations and functions of human SIRT proteins. Mol. Biol. Cell, 2005, 16, 4623-4635.
121. Balestrieri, M.L.; Rienzo, M.; Felice, F.; Rossiello, R.; Grimaldi, V.; Milone, L.; Casamassimi, A.; Servillo, L.; Farzati, B.; Giovane, A.; Napoli, C. High glucose downregulates endothelial progenitor cell number via SIRT1. Biochim. Biophys. Acta, 2008, 1784, 936-945.
122. Boily, G.; Seifert, E.L.; Bevilacqua, L.; He, X.H.; Sabourin, G.; Estey, C.; Moffat, C.; Crawford, S.; Saliba, S.; Jardine, K.; Xuan, J.; Evans, M.; Harper, M.E.; McBurney, M.W. SirT1 regulates energy metabolism and response to caloric restriction in mice. PLoS ONE, 2008, 3, e1759.
123. Wang, R.H.; Sengupta, K.; Li, C.; Kim, H.S.; Cao, L.; Xiao, C.; Kim, S.; Xu, X.; Zheng, Y.; Chilton, B.; Jia, R.; Zheng, Z.M.; Ap-pella, E.; Wang, X.W.; Ried, T.; Deng, C.X. Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell, 2008, 14, 312-323.
124. Pearson, M.; Carbone, R.; Sebastiani, C.; Cioce, M.; Fagioli, M.; Saito, S.; Higashimoto, Y.; Appella, E.; Minucci, S.; Pandolfi, P.P.; Pelicci, P.G. PML regulates p53 acetylation and premature senescence induced by oncogenic Ras. Nature, 2000, 406, 207-210.
125. Shan, H.; Bai, X.; Chen, X. Angiotensin II induces endothelial cell senescence via the activation of mitogen-activated protein kinases. Cell Biochem. Funct., 2008, 26, 459-466.